GO8246: Cancer Genomics Clinical Trials Fund: SCCT Program

The Cancer Genomics Clinical Trials Fund (the Fund) is a one-off grant opportunity that will run over three years, FY2025-26 through to FY2027-28.

The Fund will direct additional investment to Australia's Multi-site Collaborative Cancer Clinical Trials Groups (CTGs) under the Support for Cancer Clinical Trials (SCCT) program to build capacity and develop approached of methods to set the foundation for, and accelerate the incorporation of genomics into the design of cancer clinical trial concepts and protocols to benefit all CTGs.

For further information please refer to the Cancer Genomics Clinical Trials Fund Grant Opportunity Guidelines.

The Fund is directed to Australia's Multi-site Collaborative Cancer Clinical Trials Groups (CTGs) under the Support for Cancer Clinical Trials (SCCT) program.

Grantees must comply with the Agreement terms, continue to meet the eligibility obligations relating to the National Redress Scheme as set out in the relevant grant opportunity guidelines, and provide required insurances (Public Liability not less than $10,000,000; Professional Indemnity not less than $5,000,000; Workers Compensation as required by applicable state/territory law).

Grantees must provide the reporting and invoicing specified in the Agreement, maintain records and financial accounts, and use the Grant consistent with the Activity Budget and Grant Details.

The Activity starts on execution of the Grant Agreement and (other than final reports) ends on 2028-06-30.